Meeting
2011 Breast Cancer Symposium
Effect of oral cyclophosphamide use on pathologic complete response rate in the neoadjuvant treatment of breast cancer.
Authors
M. Luque
Asturias Central University Hospital, Oviedo, Spain
M. Luque , P. Garcia-Teijido , Y. Fernandez , T. Sampedro , V. Reguero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Reception and General Poster Session D
Track
Prevention, Survivorship & Health Policy,Systemic Therapy
Sub Track
New Systemic Agents – Cytotoxics
Citation
J Clin Oncol 29, 2011 (suppl 27; abstr 276)
Abstract #
276
Poster Bd #
C19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2015 Breast Cancer Symposium
Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH).
First Author: Rosana Gnanajothy
Poster
2013 ASCO Annual Meeting
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
First Author: Takashi Ishikawa